The University of Southampton
University of Southampton Institutional Repository

Novel markers to detect recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes

Novel markers to detect recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes
Novel markers to detect recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes
Insulin-like growth factor-I (IGF-I) is abused by elite athletes for its metabolic and anabolic effects. We have previously shown that it is possible to detect IGF-I misuse by measuring serum IGF-I and procollagen type III amino-terminal propeptide (P-III-NP) but a pilot study suggested measuring IGF-II, IGF binding protein-2 (IGFBP-2) and acid-labile subunit (ALS) may improve the detection of IGF-I administration. The aim of the study was to assess this in a randomized controlled trial. Twenty-six female and 30 male recreational athletes were randomized to 28?days’ treatment with placebo or recombinant human (rh)IGF-I/rhIGF binding protein-3 (IGFBP-3) complex (30?mg/day or 60?mg/day), followed by 56?days’ washout. IGF-II, IGFBP-2 and ALS (women only) were measured using commercial immunoassays. IGFBP-2 increased and IGF-II decreased in response to both low and high dose rhIGF-I/rhIGFBP-3 in both women and men while ALS decreased in women in response to high dose rhIGF-I/rhIGFBP-3. Two days after discontinuing treatment, significant differences remained between the three treatment groups in IGFBP-2 and IGF-II, but not ALS. Thereafter there were no significant differences between the three treatment groups in any of the markers. Combining IGF-I with IGF-II and/or IGFBP-2 improved the performance of the test to detect rhIGF-I/rhIGFBP-3 administration in both women and men
1942-7603
Holt, Richard
d54202e1-fcf6-4a17-a320-9f32d7024393
Guha, Nishan
38212040-a65e-4874-a60a-21f0ae3bdf09
Böhning, W.
d862f4db-88a4-4628-b678-96d377264f72
Bartlett, C.
fdad05d5-46a9-44f1-8554-65d78f0c4523
Cowan, D.A.
12cb2fe2-013f-4576-a834-aec644df8a06
Sönksen, P.H.
e2efe20d-b58b-4767-aa12-49f55ed2063a
Böhning, D.
52e66c7f-b1a2-4535-a144-8bdcd7544909
Holt, Richard
d54202e1-fcf6-4a17-a320-9f32d7024393
Guha, Nishan
38212040-a65e-4874-a60a-21f0ae3bdf09
Böhning, W.
d862f4db-88a4-4628-b678-96d377264f72
Bartlett, C.
fdad05d5-46a9-44f1-8554-65d78f0c4523
Cowan, D.A.
12cb2fe2-013f-4576-a834-aec644df8a06
Sönksen, P.H.
e2efe20d-b58b-4767-aa12-49f55ed2063a
Böhning, D.
52e66c7f-b1a2-4535-a144-8bdcd7544909

Holt, Richard, Guha, Nishan, Böhning, W., Bartlett, C., Cowan, D.A., Sönksen, P.H. and Böhning, D. (2016) Novel markers to detect recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes. Drug Testing and Analysis. (doi:10.1002/dta.1941). (PMID:26888146)

Record type: Article

Abstract

Insulin-like growth factor-I (IGF-I) is abused by elite athletes for its metabolic and anabolic effects. We have previously shown that it is possible to detect IGF-I misuse by measuring serum IGF-I and procollagen type III amino-terminal propeptide (P-III-NP) but a pilot study suggested measuring IGF-II, IGF binding protein-2 (IGFBP-2) and acid-labile subunit (ALS) may improve the detection of IGF-I administration. The aim of the study was to assess this in a randomized controlled trial. Twenty-six female and 30 male recreational athletes were randomized to 28?days’ treatment with placebo or recombinant human (rh)IGF-I/rhIGF binding protein-3 (IGFBP-3) complex (30?mg/day or 60?mg/day), followed by 56?days’ washout. IGF-II, IGFBP-2 and ALS (women only) were measured using commercial immunoassays. IGFBP-2 increased and IGF-II decreased in response to both low and high dose rhIGF-I/rhIGFBP-3 in both women and men while ALS decreased in women in response to high dose rhIGF-I/rhIGFBP-3. Two days after discontinuing treatment, significant differences remained between the three treatment groups in IGFBP-2 and IGF-II, but not ALS. Thereafter there were no significant differences between the three treatment groups in any of the markers. Combining IGF-I with IGF-II and/or IGFBP-2 improved the performance of the test to detect rhIGF-I/rhIGFBP-3 administration in both women and men

Text
DTA-2015-0281Holtetalrevised FINAL.docx - Accepted Manuscript
Download (126kB)

More information

Accepted/In Press date: 3 December 2015
e-pub ahead of print date: 17 February 2016
Organisations: Faculty of Medicine

Identifiers

Local EPrints ID: 394700
URI: http://eprints.soton.ac.uk/id/eprint/394700
ISSN: 1942-7603
PURE UUID: fd5855bf-323e-4adb-b5df-dea343489242
ORCID for Richard Holt: ORCID iD orcid.org/0000-0001-8911-6744

Catalogue record

Date deposited: 20 May 2016 10:33
Last modified: 18 Feb 2021 16:56

Export record

Altmetrics

Contributors

Author: Richard Holt ORCID iD
Author: Nishan Guha
Author: W. Böhning
Author: C. Bartlett
Author: D.A. Cowan
Author: P.H. Sönksen
Author: D. Böhning

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×